Drug Search Results
More Filters [+]

Encainide

Alternative Names: encainide
Latest Update: 2023-07-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Ireland

Approved Indications: None

Known Adverse Events: None

Company: National Heart, Lung, and Blood Institute (NHLBI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Encainide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Myocardial Ischemia|Death, Sudden, Cardiac|Myocardial Infarction|Coronary Artery Disease|Cardiac Arrest

Phase 2: Death, Sudden, Cardiac|Ventricular Fibrillation|Cardiac Arrhythmias|Myocardial Infarction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00000504

P2

Completed

Death, Sudden, Cardiac|Cardiac Arrhythmias|Ventricular Fibrillation|Myocardial Infarction

None

CAST

P3

Completed

Myocardial Infarction|Coronary Artery Disease|Myocardial Ischemia|Death, Sudden, Cardiac|Cardiac Arrest

None

Recent News Events